Sonawane T, et al
Using longitudinal prescription databases, we examined dosage formulation distributions at 3-month intervals from baseline up to 12 months post-index for incident and prevalent users of the three GLP-1 RAs of interest in France and Italy
They're just part of the terrain, and it's terrain we know how to navigate together
Most Ozempic-related headaches are mild, temporary, and manageable with hydration, balanced nutrition, and thoughtful dose adjustments
Per Trimi's published terms, its program operates on a recurring billing model
2 CKD confirmatory secondary endpoints Significant 18% RRR of MACE with Ozempic 2 For adults with T2D and CKD, for a confirmatory secondary endpoint: Time to first occurrence of MACE (CV death, nonfatal MI, or nonfatal stroke) vs placebo when both were added to standard of care 1,2 Time to first MACE 1-3,w-z 1-3,w-z w Cumulative incidence estimates are based on time from randomization to first EAC-confirmed MACE with non-CV death modelled as a competing risk using the Aalen-Johnson estimator
